Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Pharmacokinetic Study of BI 764198 XX (C‑14) and [4-(6‑aminopyridazin‑3‑yl)piperidin‑1‑yl][5-(4‑fluorophenoxy)-4‑methoxypyridin‑2‑yl]methanone in Healthy Men

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study involves healthy adult men and examines a single dose of the investigational drug BI 764198 given as a 40 mg oral solution. The medication is taken by mouth in liquid form and is being evaluated to see how it behaves inside the body.

The purpose of the study is to investigate how the drug is processed in the body. Participants will receive one dose of the oral solution and then provide urine and stool samples over several days while blood samples are taken at set times to measure the amount of drug present. This allows researchers to understand the drug’s pharmacokinetics—how it is absorbed, distributed, broken down into metabolites, and eliminated. By tracking the total amount of radioactivity recovered in urine and feces, the study assesses the mass balance of the drug, which shows what proportion of the dose is excreted and through which routes.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline assessments

    After joining the study, basic health checks are performed to confirm that you are a healthy male volunteer. these checks may include measurements of vital signs, simple blood tests, and a review of medical history.

  2. Step 2

    Single oral dose of study medication

    You will receive one oral dose of bi 764198 xx (c-14) as an oral solution. the dose is 40 mg and is taken only once.

    In the arm that uses the microtracer approach, you will also receive a single oral dose of [4-(6-aminopyridazin-3-yl)piperidin-1-yl][5-(4-fluorophenoxy)-4-methoxypyridin-2-yl]methanone as an oral solution. this dose is also 40 mg and taken only once.

  3. Step 3

    Blood sample collection

    After the dose, blood samples will be taken at several time points to measure the amount of the medication and its breakdown products in your bloodstream. samples are collected until the last measurable point, which may be several hours or days after dosing.

  4. Step 4

    Urine and feces collection

    You will be asked to provide all urine and feces you produce after dosing. these collections continue until the study team determines that the total radioactivity from the medication can no longer be measured, which helps assess how the body eliminates the drug.

  5. Step 5

    Final assessments and study completion

    Once all required samples have been collected and the measurements are complete, a final health check is performed. after this check you are released from the study.

Who can join the trial?

4 criteria

  • Be a male who is in good health, confirmed by a doctor after reviewing your medical history (record of past illnesses), completing a physical examination (a check‑up by a physician), measuring your vital signs such as blood pressure (the force of blood in your arteries) and pulse (heart beats per minute), performing a 12‑lead ECG (a test that records the heart’s electrical activity), and doing routine clinical laboratory tests (blood and urine tests).
  • Be between 18 and 65 years old, inclusive.
  • Have a Body Mass Index (BMI) between 18.5 and 29.9 kg/m². BMI is a simple calculation that compares your weight to your height to assess whether you are underweight, normal weight, or overweight.
  • Provide a signed and dated written informed consent before joining the study. This means you agree in writing after the study has explained its purpose, procedures, risks, and benefits. The consent follows ICH‑GCP (international guidelines for good clinical practice) and local laws.

Who cannot join the trial?

6 criteria

  • Any abnormal result in the medical exam (including blood pressure, pulse rate or ECG, which is a test that records the heart’s electrical activity) that the doctor decides is important.
  • Repeated blood pressure readings that are too low or too high: the top number (systolic) must be between 90 and 140 mmHg, the bottom number (diastolic) must be between 45 and 90 mmHg, and the pulse rate must be between 40 and 100 beats per minute.
  • Any laboratory value (such as blood or urine test) that is outside the normal reference range and the doctor considers it clinically relevant.
  • Any other disease that the doctor judges to be important for the study (concomitant disease).
  • Disorders of the stomach or intestines (gastrointestinal), liver (hepatic), kidneys (renal), lungs (respiratory), heart and blood vessels (cardiovascular), how the body uses food (metabolic), immune system (immunological) or hormone system (hormonal).
  • Any additional reasons listed in the study protocol.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • BI 764198 XX (C-14)

    is an experimental medicine being studied for the first time in people. In this trial it is taken as a single dose of liquid that you swallow. The purpose of giving this drug is to learn how quickly it is absorbed, how it spreads through the body, how it is broken down, and how it leaves the body. By watching these steps the researchers can understand the basic behavior of the medicine.

  • [4-(6-AMINOPYRIDAZIN-3-YL)PIPERIDIN-1-YL][5-(4-FLUOROPHENOXY)-4-METHOXYPYRIDIN-2-YL]METHANONE

    is a specially designed version of the same experimental drug that contains a very small amount of a harmless radioactive marker. It is also taken as a liquid you swallow. The tiny radioactive tag lets scientists track exactly where the drug goes inside the body and how it is processed, giving detailed information about its metabolism and excretion.

What is already known about the treatment

  • BI 764198 XX (C-14)

    This medication is given as a 40 mg oral solution that is swallowed by mouth. It is currently an investigational drug and has not yet been approved for any medical use, appearing only in early research studies. The trial is looking at its possible use for heart‑related conditions, although no specific treatment claim is established. It works by interacting with proteins that control blood vessel tone, and it is classified as an experimental small‑molecule cardiovascular agent.

  • [4-(6-AMINOPYRIDAZIN-3-YL)PIPERIDIN-1-YL][5-(4-FLUOROPHENOXY)-4-METHOXYPYRIDIN-2-YL]METHANONE

    This substance is also administered as a 40 mg oral solution taken by mouth. It is a radiolabeled version used only in research and has no approved medical status. The study uses it to help understand how BI 764198 is processed in the body, not to treat a disease directly. It acts by marking the drug’s molecules so scientists can track them, and it belongs to the class of investigational radiolabeled tracer compounds.

Investigated diseases

Cardiovascular disease - Cardiovascular disease refers to disorders that affect the heart and blood vessels. It often starts with the buildup of fatty deposits in arteries, which narrows them and reduces blood flow. Over time, the reduced flow can cause the heart muscle to work harder, leading to thickening of the heart walls. The condition may also cause blood clots that block vessels, further limiting circulation. As the disease advances, symptoms such as chest discomfort, shortness of breath, or swelling may appear.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2022-502327-22-00Protocol code1434-0016Estimated enrolment16 patientsSponsorBoehringer Ingelheim International GmbH

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.